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Abstract
Background: Therapeutic potential was evaluated in a rat model of myocardial infarction using nanofiber-expanded human
cord blood derived hematopoietic stem cells (CD133+/CD34+) genetically modified with VEGF plus PDGF genes (VIP).
Methods and Findings: Myocardial function was monitored every two weeks up to six weeks after therapy.
Echocardiography revealed time dependent improvement of left ventricular function evaluated by M-mode, fractional
shortening, anterior wall tissue velocity, wall motion score index, strain and strain rate in animals treated with VEGF plus
PDGF overexpressed stem cells (VIP) compared to nanofiber expanded cells (Exp), freshly isolated cells (FCB) or media
control (Media). Improvement observed was as follows: VIP.Exp. FCB.media. Similar trend was noticed in the exercise
capacity of rats on a treadmill. These findings correlated with significantly increased neovascularization in ischemic tissue
and markedly reduced infarct area in animals in the VIP group. Stem cells in addition to their usual homing sites such as
lung, spleen, bone marrow and liver, also migrated to sites of myocardial ischemia. The improvement of cardiac function
correlated with expression of heart tissue connexin 43, a gap junctional protein, and heart tissue angiogenesis related
protein molecules like VEGF, pNOS3, NOS2 and GSK3. There was no evidence of upregulation in the molecules of oncogenic
potential in genetically modified or other stem cell therapy groups.
Conclusion: Regenerative therapy using nanofiber-expanded hematopoietic stem cells with overexpression of VEGF and
PDGF has a favorable impact on the improvement of rat myocardial function accompanied by upregulation of tissue
connexin 43 and pro-angiogenic molecules after infarction.
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Introduction
Recent reports indicate that infusion of hematopoietic stem/
progenitor cells is an important therapeutic approach for the
treatment of hematological malignant and ischemic diseases
[1,2,3,4,5,6]. However, insufficient number of donor stem cells,
cell viability and inefficient expansion techniques limit its clinical
application [1,2,3,4]. Therefore, an efficient and practical ex vivo
stem cell expansion methodology is critical, which would maintain
the expanded stem cell’s potential for engraftment, differentiation
and long-term sustainability [7]. Stem cells in bone marrow
generally maintain the ability to balance self-renewal and
commitment to differentiation, whereas in culture, they tend to
lose their self-renewal ability after proliferation [7].
Accordingly, to maintain self-renewal ability of stem cells, a
stromal-free suspension culture has been rapidly adopted as an
alternative to stromal layer culture for stem cell expansion due to
their chemically defined nature. The use of various combinations
of growth factors and cytokines in suspension culture to substitute
for the regulatory signals provided by stromal cells has been
utilized [8,9]. Previous studies from our group and others using
stromal-free culture, have shown that the human umbilical cord
blood derived CD133+/CD34+ cells can be expanded efficiently
on aminated nanofibers for 10 days using serum-free medium
[10]. However, their functionality and potential therapeutic
efficacy have not yet been clearly defined for treatment of
myocardial infarction.
Ischemic heart disease is a major health concern in both the
industrialized and developing world. Despite advances in myo-
cardial reperfusion strategies and novel pharmacological ap-
proaches, therapies directed towards the deleterious consequences
of acute and chronic myocardial ischemic damage remain limited.
Myocyte replication and myocardial regeneration have been
documented in the human heart after acute myocardial infarction
and in chronic ischemic cardiomyopathy. In addition, experimen-
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stem and progenitor cells into the myocardium has a favorable
impact on tissue perfusion and contractile performance [11],
which have been corroborated with neovascularization and
myocyte formation [12,13,14].
Collateral circulation in ischemic heart disease plays a critical
role in myocardial ischemia. Recently, novel approaches that may
augment collateral circulation in ischemic heart disease have been
tested in preclinical and clinical studies. Gene transfer of
angiogenic growth factors has been reported to attenuate tissue
ischemia through stimulating angiogenesis at sites of neovascular-
ization [15,16,17]. Studies with plasmid vectors of vascular
endothelial growth factor VEGF-A164, or platelet derived growth
factor PDGF-BB, or a combination of the two [18] confirmed
unique roles of each gene. Capillary density was primarily
increased with VEGF-A164 while arteriolar growth was preferen-
tially stimulated by PDGF-BB. However, combination of both
genes resulted in increase of both capillaries and arterioles in
animal models. Furthermore, combined stimulation with VEGF-
A, fibroblast growth factor (FGF-2), or PDGF-BB has also
emerged as a potent strategy for therapeutic angiogenesis [19].
Circulating CD34+ progenitor cells isolated from the peripheral
blood of adult humans [20,21,22], represent an alternative
approach. There is increasing evidence to suggest that part of
the favorable impact of angiogenic growth factor therapy involves
the mobilization of bone marrow-derived progenitor stem cells
from host cells [23,24,25].
In the present study, using ex vivo nanofiber scaffold and serum-
free expansion technology, we successfully expanded human
umbilical cord blood-derived CD133+/CD34+ progenitor cells
without promoting differentiation. We further transiently overex-
pressed angiogenic genes VEGF and PDGF in ex vivo expanded
stem cells using a bicistronic vector, in which both VEGF-A164
and PDGF-BB genes are within the internal ribosomal entry site
under CMV promoter, to augment stem cell effect for treatment of
myocardial ischemia induced in rat model. The underlying
mechanisms of stem cell-therapeutic effect were also investigated.
Results
Isolation, Expansion and Genetic Modification of Cord
Blood Derived Progenitor Cells
CD133+ cells isolated from freshly collected umbilical cord
blood samples using Auto MACS system were of greater than 95%
purity. Cells were expanded (225-fold within 10 days) on nanofiber
matrices preserving stem cell phenotype [26].
Transfection of Expanded Progenitor Cells with Coupled
VEGF and PDGF
Nanofiber-expanded progenitor cells were transfected, using the
Amaxa electroporation protocol described earlier [26]. Transfec-
tion efficiency with pmaxGFP vector was more than 90% and cell
viability was ,70%. However, when used VEGF and PDGF
containing (VIP) vector transfection efficiency was ,60%, and cell
viability was also ,60%. Reduced transfection efficiency and cell
viability were likely due to the larger plasmid size.
Angiogenic Factors-Overexpressed Stem Cell Therapy
Reduces Myocardial Infarct Area
Paraffin blocked sections of harvested rat heart tissue after 6
weeks of stem cell therapy or control groups were stained with
Masson’s trichome staining and viewed under low powered
microscope (Figure 1). Total fibrosis was measured by using
Figure 1. Evaluation of total ischemic area using Masson’s trichrome staining. Paraffin-blocked tissues from infarct zones were sectioned
and stained with Masson’s trichrome after six weeks of therapy demonstrating decreased infarct size in VIP , Exp , FCB , Med groups. Five sections
were examined from each heart. Four hearts from each group were evaluated. Every section was examined with low power field to visualize gross
heart morphology, and to visualize fibrous tissues after ischemia, and area of interest of each heart section is magnified. Representative gross heart
pictures are shown here with areas of interest in higher magnification.
doi:10.1371/journal.pone.0007325.g001
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reported as percent fibrosis of total heart. Med =17.8761.84,
FCB =16.1060.89, Exp =15.3361.43 and VIP =11.0461.82.
Animals in the VIP group had reduced fibrous area compared to
other groups. A modest reduction in scar was also observed in the
Exp group.
Improved Heart Function after Therapy with Stem Cells
Overexpressing Angiogenic Factors
After six weeks of therapy, a remarkable improvement in
anterior wall motion by M-mode echocardiography was observed
in the VIP group. There was also a remarkable improvement in
the Exp group compared to FCB or Med groups (Figure 2A).
Other parameters such as fractional shortening (FSa; VIP=
0.4460.04, Exp=0.3260.02, FCB=0.2860.03, Med=
0.3560.05), anterior wall tissue velocity (TVa; VIP=0.3460.07,
Exp=0.1860.08, FCB=0.1460.04, Med=0.1260.04), and wall
motion score index (WMSI; VIP=1.460.1, Exp=1.660.1,
FCB=1.960.1, Med=1.560.1) were also markedly improved
in the VIP group (Figure 2B) compared to the other groups. Strain
(VIP=4.0761.15, Exp: 2.5761.33, FCB: 1.3460.25, Med:
0.8160.08), and strain rates (VIP =0.87, Exp =0.58, FCB =
0.46, Med =0.28) were also increased in a time dependent fashion
in the VIP group compared to other groups (Figure 2C).
Improved Heart Function Correlates with Increased
Neovascularization
Capillary density was measured after alkaline phosphatase
staining, as described earlier, in the cryo-preserved heart tissue
as an anatomical marker of induced angiogenesis. Total
percent capillary area per high power field was as follows:
VIP=7.4460.98, Exp=7.3360.91, FCB=6.8261.13, and
Med=6.7360.6. Total capillary was also counted and mean
capillary number per high power field is as follows:
VIP=886.06200.9, Exp=523.96100.3, FCB=272.0649.6,
and Med=177625.1. Neovascularization was much more evident
in the VIP group compared to other groups, verified by
immunostaining and total capillary density (Figure 3).
Improved Cardiac Function Results in Increased Exercise
Capacity on Treadmill
A modest but significant improvement of exercise capacity was
observed in animals in the VIP group compared to those in the
Med group (Figure 4). A smaller degree of improvement was also
observed in the Exp and FCB groups.
Stem Cells Home to Ischemic Region of the Heart
As demonstrated here, stem cells migrate to lung, spleen and
liver (Figure 5A). However, stem cells were also observed to home
to ischemic zones of the heart (Figure 5A). Cell numbers were
counted per high power field per organ and were as follows:
Lung=2168 cells, Spleen=75612 cells, Liver=562 cells and
Heart=1364 cells. Migrated stem cells were also found to
differentiate into endothelial cells within the arterioles and
capillaries in the myocardium (stained with human specific vWF,
Figure 5B).
Upregulation of Gap Junctional Protein Connexin 43
Gap junctional protein connexin 43, which is a major factor
responsible for cardiomyocyte contractile function, was found to
have higher expression in the VIP group compared to others
(Figure 6). However, modestly increased expression of connexin 43
was also found in animals in the Exp group compared to those in
the FCB and Med groups (Figure 6).
Evaluation of Signals Responsible for Angiogenesis
Total protein isolation and Western blots were performed on
snap-frozen heart tissue to assess levels of each individual protein
that may play a role in angiogenesis (Figure 7A). Animals in the
VIP group had elevated levels of VEGF (9.2162.19 fold) and
phosphorylation of pNOS3 (2.6460.48 fold) and connexin 43
(4.1960.57 fold) compared to Med control group. A modest
increase was also found in NOS2 (2.2160.44 fold) and GSK3
(1.4460.13 fold) expression in the VIP group. A significant
reduction of matrix metalloproteinase 9 (MMP 9; 0.5360.11 fold)
was observed in animals treated with VIP compared to others. A
modest increase in VEGF (2.0660.24 fold) and connexin 43
(3.0560.55 fold) levels were also found in the Exp group
compared to Med control group. GAPDH and b-actin were used
as internal loading controls.
Evaluation of Molecules of Oncogenic Potential and
Relevant Signaling Pathways
The oncogenic potential of angiogenic factor overexpression
was evaluated with no significant inductions in the levels of PTEN,
pPTEN, ERK1/2, pERK K, AKT, p38, p21 and caspase 3 in
heart tissues of animals in the VIP group compared to others
(Figure 7B).
Discussion
The availability of adequate quantity of functional hematopoi-
etic stem cells for functional dose-response is one of the major
limitations of regenerative cell based therapy. However, our
nanofiber-mediated expansion technology provides a unique
opportunity to overcome this deficiency. We have previously
shown that freshly isolated CD133+ stem cells can be expanded
225-fold in 10 days after culturing them in a serum-free medium
on a nanofiber scaffold [26]. We have also demonstrated that these
expanded cells retain their progenitor cell phenotypes with respect
to multipotential differentiation and migration [26]. As it is not
known whether these nanofiber-expanded stem cells are biolog-
ically active to be used clinically for the treatment of myocardial
ischemia, we sought to investigate the functional role of these cells
in a rat myocardial infarction model.
Cell based therapeutic approaches may prevent deterioration of
the myocardial function post infarction and may even reverse
established heart failure. However, the original concepts regarding
cell-based therapies have proven to be overly simplistic since
generation and engrafment of new muscle alone is insufficient for
the approach to be successful. It appears that nonmyogenic
mechanisms are important for majority of the beneficial trophic
effects observed during cell-based therapies [27,28]. Therefore,
elucidation of these specific mechanisms is essential to improve
cell-based therapies.
In the present study, we first expanded stem cells ex vivo on
nanofiber-coated plates and then overexpressed VEGF and PDGF
in these cells to enhance their vasculogenic potential [29,30,31].
Previous studies of autologous BM-derived CD133+ cells injected
either via intracoronary infusion [32] or intramyocardial injection
[33] augmenting vasculogenesis in patients with myocardial
ischemia [34] prompted us to investigate the potential of
genetically modified stem cells in ischemic heart disease.
Furthermore, the limited availability of functional progenitor cell
population in bone marrow and peripheral circulation [35] and
compromised potential of these cells in disease states and aged
Stem Cells Heal Infarct Heart
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therapy demonstrating improved anterior wall motion in the VIP . Exp . FCB . Med groups. Inset shows the short axis two-dimensional image of
the LV. (B) Echocardiographic parameters of cardiac function using fractional shortening (FSa), anterior wall tissue velocity (TVa) and wall motion
score index (WMSI) plotted as a function of time within each group demonstrating significant improvement in function in the VIP group compared to
controls. (C) Strain and strain rates presented as a function of time within each group with significant improvement in the VIP group.
doi:10.1371/journal.pone.0007325.g002
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mechanisms of successful cell-based therapy in these subjects.
Our current findings thus provide the feasibility and effectiveness
of overexpressing angiogenic growth factors on nanofiber
expanded hematopoietic stem cells for the treatment of myocardial
infarction. The overexpression of angiogenic factors not only
promotes neovascularization in the ischemic heart tissues, but
thereby significantly improves several parameters of cardiac
function including fractional shortening, tissue velocity, wall
motion score index, strain and strain rate. Accordingly, with
improved heart function, animals demonstrate better exercise
capacity implying functional improvement. In addition, the
reduction in myocardial fibrosis in these animals is also an
important indicator for improved heart function since late
reperfusion of infarcted vascular beds attenuates left ventricular
remodeling including infarct expansion [38,39].
In addition to myogenesis, vasculogenesis [40] and anti-
apoptotic effects of the paracrine factors secreted by hematopoietic
stem cells [41], our findings also indicate that the hematopoietic
stem cells home to injured sites besides their usual destinations
such as lung, liver, spleen and bone marrow. This phenomenon
therefore suggests that both trans-differentiation and paracrine
mechanisms might be operational in our therapeutic approach.
Nanofiber expanded stem cells express significantly more CXCR4
and high concentrations of SDF-1 in ischemic or damaged tissues,
which may be responsible for increased homing as CXCR4 is a
natural receptor for SDF-1 [42,43]. As we report, hematopoietic
Figure 3. Evaluation of neovascularization. Cyro-preserved sections were stained with alkaline phosphatase, and were evaluated capillary
density area (%) per high power field (A), and total capillary number per high power field (B) in histochemistry images. Representative images of each
group (C) were shown in the lower panel. Capillary count and total capillary areas (A & B) were measured by Image Quant software demonstrating
highest capillary area density in the VIP group.
doi:10.1371/journal.pone.0007325.g003
Figure 4. Measurement of exercise capacity. Exercise capacity was
evaluated by time on a graded treadmill after six weeks of therapy
demonstrated an incremental time in the order of VIP . Exp . FCB .
Med groups.
doi:10.1371/journal.pone.0007325.g004
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such as the lung, liver, spleen and bone marrow. In this homing of
stem cells both transdifferentiation and paracrine mechanisms
might be involved. In cardiac tissues, infused stem cells
differentiate into endothelial cells and integrate into the inner
lining of microvasculature under influence of microenvironment.
We have previously demonstrated that nanofiber expanded stem
cells maintain the ability to multi-potentially differentiate into
endothelial and smooth muscle cells, hence, contributing to
vasculogenesis [26]. A recent report indicated that hematopoietic
stem cells integrated into rat myocardial ischemic tissues and
organs could be detected even one month after injection [44]. The
involvement of paracrine mechanisms to mediate the therapeutic
effects of stem cells in various ischemia models have also been
demonstrated [45]. In murine ischemic models, bone marrow
stromal cells have been shown to enhance collateral flow recovery
and remodeling, thereby attenuating muscle atrophy [46].
Moreover in rat myocardial infarction models, collaterals and
improved cardiac function have been demonstrated using CD34+
stem cell therapy [40]. However, our approach of combining
angiogenic growth factors and overexpressing them in nanofiber
expanded stem cells, resulted in significant enhancement of
neovascularization and improvement of cardiac function com-
pared to stem cell injection alone. In addition, to the pro-
angiogenic effect of VEGF, this marked improvement of
neovascularization may also be due to enhanced maturating effect
[29,47] and inhibition of apoptosis by PDGF [48].
To further elucidate the precise mechanisms of the improved
effects of angiogenic growth factors overexpressed in nanofiber
expanded stem cells on neovascularization and cardiac function,
we evaluated the role of signaling molecules in ischemic rat hearts.
We observed a significant increase in the production of VEGF,
pNOS3 and NOS2 and decrease in the production of MMP9 in
rat heart tissues treated with stem cells overexpressing VEGF and
PDGF genes. Since the contribution of angiogenic factors from
transfected genes are limited, this type of transfection does not
sustain greater than two weeks and only transiently produces these
gene products. We, in our current study, noted a similar lower
degree of tissue expression of VEGF and NOS2 in tissues
harvested after six weeks of stem cell therapy in the Exp group,
thereby indicating that stem cell therapy itself induces host tissue
production of angiogenic factors, which in turn leads to
neovascularization of ischemic tissues. In addition, animals in
the VIP group had enhanced tissue production of angiogenic
factors, which may have been due to initiation of the signaling
cascade and initial effects of VEGF and PDGF produced by the
stem cells, further contributing to angiogenesis in the host tissue.
Finally, the concern that transient overexpression leads to tumor
formation was addressed by testing for molecules of oncogenic
potential and their signaling pathways. As we did not detect
enhanced production of these molecules or their signaling
pathways of oncogenesis, these results are encouraging for
potential clinical use of nanofiber-expanded stem cells.
In summary, we have demonstrated that significantly increased
expansion of cord blood-derived stem cells is possible using
functional nanofibers and serum-free culture media. These
expanded stem cells retain their progenitor cell phenotype and
provide an opportunity to genetically manipulate them for cell-
based therapy. We have also shown that non-viral delivery of pro-
angiogenic factors VEGF and PDGF markedly enhanced the
angiogenic effects of stem cells by increasing tissue expression of
connexin 43 and growth factors related to angiogenesis. This study
thus confirms the feasibility of combined stem cell therapy with
pro-angiogenic gene therapy. Furthermore, it also identifies the
therapeutic potential of nanofiber-expanded stem cells in treating
ischemic heart disease.
Materials and Methods
CD133+ Cell Isolation
Fresh human cord blood was obtained from University
Hospitals Case Medical Center and The Ohio State University
Figure 5. Detection of stem cell homing. (A) Immunohistochemical
detection was performed 36 hours after half a million of GFP
overexpressed nanofiber expanded stem cells injected into the left
ventricle of the rats, with fixed and paraffin embedded tissue sections
from various organs using anti-GFP Ab (right panels) against respective
controls (left panels) confirming stem cell homing to lung, spleen, liver
and heart. (B) Heart sections were stained for human specific von
Willebrand factor (vWF) and immunoglobulin G (IgG) as a control.
doi:10.1371/journal.pone.0007325.g005
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donors. Cord blood was processed following the similar protocols
published previously [26,49]. In brief, heparinized cord blood was
diluted with PBS and carefully layered over Ficoll-Paque. After 30
minutes of centrifugation in a swinging bucket rotor at 1400 rpm,
the upper layer was aspirated and the mononuclear cell layer was
collected. After several washes with PBS, mononuclear cells were
labeled with anti-CD133 monoclonal antibody conjugated to
Figure 6. Expression of gap junctional protein, connexin 43. Heart tissue sections were stained for gap junctional protein, connexin 43 from
all four groups using immunohistochemistry. Red color indicates connexin 43 stain and blue color indicates DAPI, a nuclear stain. Merged connexin
43 and DAPI of each group is displayed in micrographs.
doi:10.1371/journal.pone.0007325.g006
Figure 7. Expression of signaling molecules. (A) Western blot of angiogenesis related and connexin 43 proteins from each animal group. (B)
Western blot of various molecules of oncogenic potential and relevant signaling pathways from each animal group.
doi:10.1371/journal.pone.0007325.g007
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many). CD133+ cells were isolated by using AutoMACS cell sorter
system (Miltenyi Biotec) using double columns, following the
manufacturer’s protocol and reagents. After separation, purity of
the cell product was determined by flow cytometry.
Electrospinning, Surface Grafting and Amination of PES
Nanofiber Mesh
Electrospinning of poly-acrylic acid (PAAc), grafting onto poly-
ethyl sulfone (PES) nanofibers (MW: 55,000; Goodfellow Cam-
bridge Limited, UK) and amination were carried out according to
the procedure previously described [10].
Ex-Vivo CD133+ Hematopoietic Cell Expansion
Nanofiber mesh was secured to the bottoms of each of the 24
wells of a tissue culture plate. A total of eight hundred CD133+
cells were seeded onto each scaffold in 0.6 ml StemSpan
TM serum-
free expansion medium (SFEM; Stem Cell Technologies,
Vancouver, BC, Canada), which consists of 1% BSA, 0.01 mg/
ml recombinant human insulin, 0.2 mg/ml human transferrin,
0.1 mM 2-mercaptoethanol and 2 mM l-glutamine in Iscove’s
MDM, supplemented with 0.04 mg/ml low-density lipoprotein
(Athens Research and Technology Inc., USA), 100 ng/ml
recombinant human stem cell factor (SCF; Peprotech Inc., Rocky
Hill, NJ, USA), 100 ng/ml Flt-3 ligand (Flt3; Peprotech Inc),
50 ng/ml Thrombopoietin (TPO; Peprotech Inc) and 20 ng/ml
IL-3 (Peprotech Inc). Cells were cultured at 37 uCi na n
atmosphere containing 5% CO2 without change of medium for
10 days. Cells were harvested after 10 days of expansion by
washing once with non-trypsin cell dissociation solution and twice
with 2% FBS Hanks’ buffer at 5–10 minutes intervals between
each wash. The cell suspensions collected were then concentrated
through centrifugation at 500 6 g for 10 min. Aliquots of the
concentrated cells were then used for cell counting by a
hemocytometer, flow cytometry analysis, as well as for further
studies.
Genetic Overexpression of Angiogenic Factors on
Expanded Stem Cells
Nanofiber-expanded stem cells were transfected with green
fluorescent protein (GFP)-containing vector (pmaxGFP) and VIP
vectors (VEGF-IRES-PDGF in pAMFG vector; gift from Dr.
Blau, Stanford University, CA) using a human CD34 cell
Nucleofector kit (Amaxa Inc., Walkersville, MD) following
manufacturer’s protocol. In brief, 1–3610
6 cells were transfected
with 2–4 mg of plasmid DNA in 100 ml of CD34 cell Nucleofector
solution using Amaxa nucleoporator programs: U-008 or U-001
(Amaxa Inc., Walkersville, MD). After transfection, cells were
cultured with DMEM complete media or as stated for further
studies.
Animal Model of Myocardial Infarct
All animal experiments were performed in accordance with the
guidelines published in the ‘‘Guide for the Care and Use of
Laboratory Animals’’ (NRC publication), and under the protocols
approved by the Institutional Animal Care and Use Committee
(IACUC) at Case Western Reserve University and The Ohio State
University (University laboratory animal resources, ULAR). Male
athymic nude rats (Hsd:RH-rnu rats, Harlan Sprague Dawley,
Indianapolis, IN) aged 6 to 8 weeks were anesthetized with
intraperitoneal sodium pentobarbital (50 mg/kg). Myocardial
infarct was induced by surgical ligation of the left anterior
descending (LAD) coronary artery. Immediately before euthaniza-
tion, rats were injected with an overdose of pentobarbital.
Transplantation of Expanded and Genetically Modified
Stem Cells
Five days after myocardial infarct, rats were divided into groups
(N=6–9/group) that received intraventricular injections of 5610
5
cells that were freshly isolated (FCB), nanofiber-expanded only
(Exp), or nanofiber-expanded and angiogenic factors overex-
pressed (VIP) resuspended with 300 mL of media. The control
group received the same volume of media without cells (N=6–9).
Rats were sacrificed 6 wks after intraventricular injection.
Histological Assessment of Transplanted Animals
At necropsy, hearts were sliced in a bread-loaf fashion into 8
transverse sections from apex to base and fixed with 4%
paraformaldehyde. One half of each group of rat tissues was fixed
and embedded in OCT compound (Miles Scientific) and the other
half snap-frozen in liquid nitrogen for fluorescence microscopy
and alkaline phosphatase staining for capillary count. Paraffin-
embedded tissues were used to measure the average ratio of
fibrosis area to LV area. Capillary density was evaluated
morphometrically by histological examination of sections recov-
ered from segments of LV myocardium, subserved by the occluded
LAD. Morphometric studies were performed by a single examiner,
who was blinded to treatments.
Tracking of Stem Cell Homing
To assess the homing of stem cells, GFP overexpressed
nanofiber expanded stem cells (5610
5 cells/rat) were injected into
the rat left ventricle five days after induction of myocardial
ischemia. Thirty-six hours after cell injection, rats were sacrificed
and tissues harvested. Tissues were fixed in 10% formalin solution
and subsequently embedded in paraffin block. Five-micron
sections were cut and stained using anti-GFP antibody conjugated
with alexa fluor dye. After several washing steps, samples were
viewed under high power microscopy (Leica). Untransfected
NIH3T3 cells and GFP transfected NIH3T3 cells were used as
negative and positive controls, respectively.
Echocardiographic Analysis of LV Function
Rats were anesthetized with 3% isoflurane (maintained at ,1%
by nosecone) in a gas chamber. After shaving the chest, the
extremities were secured to a warming pad (Braintree Scientific,
MA) with paper tape and needle electrodes connected to a
preamplifier to simultaneously record a single lead electrocardio-
gram. Pre-warmed ultrasound transmission gel was applied to the
chest and 2D-directed M-mode and Doppler echocardiographic
studies were performed using a 15 MHz (15L8) linear array
transducer (Sequoia, Siemens, Mountain View, CA). Rats were
imaged in the shallow left lateral decubitus position and short and
orthogonal long axis and apical views were obtained. Echocardi-
ography was performed at baseline, 2, 4, and 6-weeks after stem
cell injection by an echo technician, who was blinded to the
therapy. Data were analyzed using software resident on the
ultrasonograph by an experienced researcher, who was also
blinded to treatment.
Measurement of Area Fractional Shortening
Area fractional shortening (FSa) was determined in both the
long axis and short axis views as the difference between the LV
diastolic area (LVDa) and LV systolic area (LVSa) divided by the
Stem Cells Heal Infarct Heart
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averaged between the long axis and short axis views.
Measurement of Wall Motion Score Index
LV wall motion score index (WMSI) was analyzed with a 13-
segment model that has previously been validated [50]. The wall
segments were visualized from two-dimensional images taken from
the parasternal long axis and from the basal and midpapillary
short axes. Regional wall motion was graded in each segment
according to the scheme adopted by the American Society of
Echocardiography, where 1 is normal, 2 is hypokinetic, 3 is
akinetic, 4 is dyskinetic, and 5 is aneurysmal [51]. Motion in the
anteroseptal and posterior wall segments was scored from the
clearer of the parasternal long or short axis, but not both. WMSI
was defined as the total of the wall motion scores divided by the
number of segments scored.
Measurement of Anterior Wall Tissue Velocity, Strain and
Strain Rate
Anterior wall tissue velocity (TVa), strain (TS), and strain rate
(TSR) were determined using Velocity Vector Imaging (VVI,
Syngo). VVI is a visual and quantitative method for assessing
cardiac mechanics using the 2D information within the image that
is based on speckle and endocardial border tracking to determine
the tissue motion throughout the cardiac cycle. The end-systolic
endocardial to mid-wall from the short axis at the papillary muscle
was manually traced from a digital cineloop frame. The velocity
vector of every point in the border is given by summation of the
border motion plus the relative velocity of the tissue with respect to
the border. Regions of interest such as the anterior wall (area of
infarct) were selected to obtain tissue velocity (cm/s), strain (%),
and strain rate (1/s) from the anterior wall (circumferential).
Measurement of Functional Exercise Capacity
To evaluate functional capacity, rats were placed on an open
treadmill (Exer-3/6, Columbus Instruments). The treadmill
incorporates an electrified grid at the rear of the belt to provide
motivation. Rats were acclimatized to the treadmill by undergoing
a 5-minute run at 5 meters per minute without incline before their
exercise test. Subsequently, the rats are subjected to supervised,
graded treadmill exercise by staged, 3-minute increases in belt
speed alternating with incline. Exhaustion was defined as the rat
spending greater than 50% of the time or 10 consecutive seconds
on the shock grid. Exercise capacity was evaluated at baseline and
6 weeks after injection.
Capillary Staining and Counting
To determine the capillary density in the border zone of the
ischemic heart, tissues were dissected and snap frozen in liquid
nitrogen. Cryo-sections of frozen tissues were stained using an
alkaline phosphatase kit (Sigma FAST
TM BCIP/NBT (5-Bromo-
4-chloro-3-indolyl phosphate/Nitro blue tetrazolium tablets),
which were used for the detection of alkaline phosphatase activity
and stained as a substrate precipitant. For quantification of
positively stained vessels (predominantly endothelium), five
sections within the necrosis border zone of each animal were
analyzed by an investigator who was blinded with respect to the
cell treatment. Capillaries were counted in 12 randomly chosen
high-power fields (HPFs) in 5 sections per tissue and 5 animals per
group. The results were expressed as total capillary area measured
by Image software (Image J, NIH, MD).
Immunohistochemistry
Gap junctional protein connexin 43, which is a major factor
responsible for cardiomyocyte contractile function, was assessed by
immunohistochemistry, formaldehyde fixed and paraffin-embed-
ded sections of cardiac tissue harvested after six weeks of stem cell
therapy.
Evaluation of Signaling Molecules in Rat Heart Tissue
After six weeks of stem cell therapy, total protein was isolated
from snap-frozen total heart tissues by homogenization in 50 mM
Tris-Hcl buffer pH 7.5 containing 150 mM sodium chloride,
0.5% NP-40, 1 mM sodium pyrophosphate, 5 mM sodium
vanadate, 1 mM benzamidine, 1 mM sodium fluoride and
protease inhibitors. Western blotting was performed to assess the
level of each protein stated. GAPDH and b-actin were used as
internal loading controls. To analyze Western blot band densities,
we used UN-SCAN-IT Gel software (version 6.1, Silk Scientific
Corp. Utah, USA). Data provided are as fold-increase or decrease
compared to Med control. All data were corrected with respect to
GAPDH levels.
Statistical Analysis
All values are presented as mean6standard error of mean. One-
way ANOVA with Scheffe’s post hoc test for unequal sample sizes
was used to compare numeric data between the four experimental
groups. Datasets consisting of two groups only were compared by
unpaired Student’s t-test. A level of p,0.05 was considered as
significant difference.
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